This grant is for the purpose of developing innovative medical countermeasures to combat bacterial pathogens and their associated toxins. The ‘Harnessing Enzymatic Activity for Lifesaving Remedies’ (HEALR) program specifically aims to achieve this by leveraging the body’s intrinsic host degradation and deactivation pathways. Through focused research, this initiative seeks to identify and harness enzymatic activities that can effectively neutralize harmful bacterial threats and their toxic byproducts. The ultimate goal is to create novel therapeutic strategies that offer robust protection and provide critical lifesaving remedies against a wide range of challenging bacterial infections, enhancing public health preparedness and response capabilities.
Opportunity ID: 327826
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | HR001120S0052 |
| Funding Opportunity Title: | Harnessing Enzymatic Activity for Lifesaving Remedies (HEALR) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement Other Procurement Contract |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 12.910 — Research and Technology Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 2 |
| Posted Date: | Jun 24, 2020 |
| Last Updated Date: | Aug 31, 2020 |
| Original Closing Date for Applications: | Sep 17, 2020 See Full Announcement for details. |
| Current Closing Date for Applications: | Sep 29, 2020 See Full Announcement for details. |
| Archive Date: | Oct 29, 2020 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Others (see text field entitled “Additional Information on Eligibility” for clarification) |
| Additional Information on Eligibility: | All responsible sources capable of satisfying the Government’s needs may submit a proposal that shall be considered by DARPA. See the Eligibility Information section of the BAA for more information. |
Additional Information
| Agency Name: | DARPA – Biological Technologies Office |
| Description: | The goal of the HEALR program is to develop new medical countermeasures against bacterial pathogens and their toxins by leveraging host degradation and deactivation pathways. |
| Link to Additional Information: | Beta.SAM Contract Opportunities |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
BAA Coordinator
HR001120S0052@darpa.mil Email:HR001120S0052@darpa.mil |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
| Extend full proposal deadline and clarify resume inclusion. | Aug 31, 2020 | |
| Jun 24, 2020 |
DISPLAYING: Synopsis 2
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | HR001120S0052 |
| Funding Opportunity Title: | Harnessing Enzymatic Activity for Lifesaving Remedies (HEALR) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement Other Procurement Contract |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 12.910 — Research and Technology Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 2 |
| Posted Date: | Jun 24, 2020 |
| Last Updated Date: | Aug 31, 2020 |
| Original Closing Date for Applications: | Sep 17, 2020 See Full Announcement for details. |
| Current Closing Date for Applications: | Sep 29, 2020 See Full Announcement for details. |
| Archive Date: | Oct 29, 2020 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Others (see text field entitled “Additional Information on Eligibility” for clarification) |
| Additional Information on Eligibility: | All responsible sources capable of satisfying the Government’s needs may submit a proposal that shall be considered by DARPA. See the Eligibility Information section of the BAA for more information. |
Additional Information
| Agency Name: | DARPA – Biological Technologies Office |
| Description: | The goal of the HEALR program is to develop new medical countermeasures against bacterial pathogens and their toxins by leveraging host degradation and deactivation pathways. |
| Link to Additional Information: | Beta.SAM Contract Opportunities |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
BAA Coordinator
HR001120S0052@darpa.mil Email:HR001120S0052@darpa.mil |
DISPLAYING: Synopsis 1
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | HR001120S0052 |
| Funding Opportunity Title: | Harnessing Enzymatic Activity for Lifesaving Remedies (HEALR) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement Other Procurement Contract |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 12.910 — Research and Technology Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Jun 24, 2020 |
| Last Updated Date: | Jun 24, 2020 |
| Original Closing Date for Applications: | – |
| Current Closing Date for Applications: | Sep 17, 2020 See Full Announcement for details. |
| Archive Date: | Oct 17, 2020 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Others (see text field entitled “Additional Information on Eligibility” for clarification) |
| Additional Information on Eligibility: | All responsible sources capable of satisfying the Government’s needs may submit a proposal that shall be considered by DARPA. See the Eligibility Information section of the BAA for more information. |
Additional Information
| Agency Name: | DARPA – Biological Technologies Office |
| Description: | The goal of the HEALR program is to develop new medical countermeasures against bacterial pathogens and their toxins by leveraging host degradation and deactivation pathways. |
| Link to Additional Information: | Beta.SAM Contract Opportunities |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
BAA Coordinator
HR001120S0052@darpa.mil Email:HR001120S0052@darpa.mil |
Related Documents
Folder 327826 Full Announcement-HR001120S0052 -> HR001120S0052.pdf
Folder 327826 Full Announcement-HR001120S0052 -> Attachment 4 Cost Proposal Spreadsheet.pdf
Folder 327826 Full Announcement-HR001120S0052 -> Attachment 2-SOW_Template.pdf
Folder 327826 Full Announcement-HR001120S0052 -> Attachment 3-Gantt_Chart_Template.pdf
Folder 327826 Full Announcement-HR001120S0052 -> Attachment 1-Executive_Summary_Slide_Template.pdf
Folder 327826 Revised Full Announcement-HR001120S0052-Amendment-01 -> HR001120S0052-Amendment-01.pdf
Packages
| Agency Contact Information: | BAA Coordinator HR001120S0052@darpa.mil Email: HR001120S0052@darpa.mil |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| 12.910 | PKG00262311 | Aug 31, 2020 | Sep 29, 2020 | View |
Package 1
Mandatory forms
327826 RR_SF424_2_0-2.0.pdf
327826 AttachmentForm_1_2-1.2.pdf
327826 RR_Budget10_1_4-1.4.pdf
327826 RR_KeyPersonExpanded_2_0-2.0.pdf
327826 RR_PersonalData_1_2-1.2.pdf
Optional forms
327826 SFLLL_1_2-1.2.pdf
327826 RR_SubawardBudget10_30_1_4-1.4.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
